Reinhardt Michael J, Ohmstede Björn, Torres-de la Roche Luz Angela, De Wilde Rudy Leon
Clinic for Nuclear Medicine, Pius Hospital, University Medicine Oldenburg, Carl von Ossietzky University Oldenburg, 26121, Germany.
Department of Anaesthesiology and Intensive Care Medicine, Pius Hospital, University Medicine Oldenburg, Carl von Ossietzky University Oldenburg, 26121, Germany.
Breast. 2025 Feb;79:103856. doi: 10.1016/j.breast.2024.103856. Epub 2024 Dec 11.
The necessity of preoperative lymphoscintigraphy before intraoperative sentinel lymph node (SLN) identification is still unclear. The aim of the present study was to evaluate the impact of SLN imaging on intraoperative SLN detection in breast cancer patients.
Retrospective, comparative, single center study of patients with breast cancer stage pT1 and pT2 who underwent axillary staging. Group 1 included patients who underwent SLN extirpation without preoperative SLN imaging, and Group 2 included patients who underwent SLN imaging prior to surgery. Differences between groups were analyzed using T-test and chi-square test.
926 (mean age: 61.45 years) patients received subdermal injection of radiolabeled nanocolloids between tumor and axilla. SLN was identified intraoperatively in 473 of 498 patients (94.98 %) in group 1, and in 415 of 428 patients (96.96 %) in group 2 (p = 0.129). Lymphoscintigraphy detected SLN in 407 of 428 (95.09 %) patients in group 2. Due to the additional SLN imaging in group 2, the time between radiotracer injection and start of surgery was significantly prolonged (p < 0.001). A reduction of applied activity from a median of 18 MBq in group 1 to a median of 12 MBq in group 2 had no negative effect on the SLN identification.
Subdermal injection of radiolabeled nanocolloids between tumor and axilla allowed high intraoperative detection of SLN. Preoperative SLN imaging had no significant impact on the intraoperative detection but is a time-consuming and resource-intensive procedure. Prospective studies might provide further evidence to omit preoperative SLN imaging in patients with T1-2 invasive breast cancer and clinically negative axilla.
术中前哨淋巴结(SLN)识别前进行术前淋巴闪烁造影的必要性仍不明确。本研究的目的是评估SLN成像对乳腺癌患者术中SLN检测的影响。
对接受腋窝分期的pT1和pT2期乳腺癌患者进行回顾性、对比性单中心研究。第1组包括未进行术前SLN成像而接受SLN切除的患者,第2组包括术前进行SLN成像的患者。使用t检验和卡方检验分析组间差异。
926例(平均年龄:61.45岁)患者在肿瘤与腋窝之间接受了放射性标记纳米胶体的皮下注射。第1组498例患者中有473例(94.98%)术中识别出SLN,第2组428例患者中有415例(96.96%)术中识别出SLN(p = 0.129)。淋巴闪烁造影在第2组428例患者中的407例(95.09%)中检测到SLN。由于第2组增加了SLN成像,放射性示踪剂注射与手术开始之间的时间显著延长(p < 0.001)。注射活性从第1组的中位数18 MBq降至第2组的中位数12 MBq对SLN识别没有负面影响。
在肿瘤与腋窝之间皮下注射放射性标记纳米胶体可实现术中对SLN的高检出率。术前SLN成像对术中检测无显著影响,但这是一个耗时且资源密集的过程。前瞻性研究可能会提供进一步的证据,以省略T1-2期浸润性乳腺癌且腋窝临床阴性患者的术前SLN成像。